	US 12,358,921 B2
	Antiviral heterocyclic compounds
Adam Szymaniak, Boston, MA (US); Robert Leon, Sharon, MA (US); Kevin McGrath, Brighton, MA (US); Xiben Li, Lexington, MA (US); Tyler J. Mann, Brighton, MA (US); Jianming Yu, Plainsboro, NJ (US); In Jong Kim, Lexington, MA (US); Scott Mitchell, Woburn, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by ENANTA PHARMACEUTICALS, INC., Watertown, MA (US)
Filed on Apr. 6, 2023, as Appl. No. 18/131,405.
Claims priority of provisional application 63/328,400, filed on Apr. 7, 2022.
Prior Publication US 2023/0357258 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/048 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07D 519/00 (2006.01)

CPC C07D 491/048 (2013.01) [A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01)]

16 Claims

1. A compound represented by Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of:

1) Optionally substituted aryl; and

2) Optionally substituted heteroaryl;

E is selected from the group consisting of:

1) Optionally substituted aryl; and

2) Optionally substituted heteroaryl;

R₁and R₂are each independently selected from the group consisting of:

1) Hydrogen;

2) Optionally substituted —C₁-C₈alkyl;

3) optionally substituted —C₃-C₈cycloalkyl;

4) Optionally substituted 3- to 8-membered heterocycloalkyl;

5) Optionally substituted aryl;

6) Optionally substituted arylalkyl;

7) Optionally substituted heteroaryl; and

8) Optionally substituted heteroarylalkyl;

alternatively, Rand R₂are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic ring;

R₃is hydroxy or fluorine; and

R₄is selected from the group consisting of:

1) Optionally substituted aryl;

2) Optionally substituted arylalkyl;

3) optionally substituted heteroaryl; and

4) Optionally substituted heteroarylalkyl.